Platelet IndicesNCT07076732
Beyond Platelet Indices, WBC-to-MPV Ratio in Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA) Correlate With Short-Term Rather Than In-Hospital Outcomes
An observational study of Platelet Indices and White Blood Cell, run by Sohag University at 1 site in Egypt.
Trial summary
This study aims to evaluate the role of platelet indices and the [White blood cell (WBC) /mean platelet volume (MPV)] ratio in correlation with angiographic profiles of patients diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA) to assess their predictive value for short-term clinical… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Platelet Indices, White Blood Cell, Mean Platelet Volume
- What is being tested?
- Coronary Angiography and SYNTAX Score
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2025to 10 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This case-control study will be performed at Sohag University Hospitals after approval from the institutional ethical committee.
Who may be able to join
- Age ≥18 years old.
- Both sexes.
- Patients with acute myocardial infarction (AMI). Myocardial infarction with nonobstructive coronary arteries (MINOCA) is diagnosed if a patient fulfilled the AMI criteria in the absence of obstructive coronary arteries (type I: <50% stenosis; or type II: no stenosis) as recommended by the recent American Heart Association statement that introduces an updated definition incorporating the 4th universal MI definition, which by agreement excludes Takotsubo syndrome and myocarditis from the eventual diagnosis of MINOCA.
Who cannot join
- Previous history of MI or coronary revascularization (PCI or bypass surgery) with acute/chronic infection.
- Autoimmune diseases.
- Systemic inflammatory disease.
- Patients on treatment therapy which critically affects inflammatory cell count.
- Patients with malignancy.
- Chronic kidney disease.
Show all 9Show fewer
- Severe liver disease.
- Severe anemia.
- Fever (>38°C).
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to evaluate the role of platelet indices and the [White blood cell (WBC) /mean platelet volume (MPV)] ratio in correlation with angiographic profiles of patients diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA) to assess their predictive value for short-term clinical outcomes.
Read the detailed description
Globally, ischemic heart disease remains a significant cause of death, and its prevalence constantly increases. Around 5-15% of acute myocardial infarction (AMI) patients show nonobstructive (<50% stenosis) coronary arteries, named myocardial infarction with nonobstructive coronary arteries (MINOCA).
There are two main phases of inflammation during myocardial infarction: the inflammatory phase and the proliferative phase. The white blood cell (WBC) count and its subtypes have been investigated as potential predictors of cardiovascular outcomes in patients with coronary artery disease (CAD), serving as inflammatory markers.
The mean platelet volume (MPV) is determined in the progenitor cell, the bone marrow megakaryocyte. The platelet volume is found to be associated with cytokines (thrombopoietin, interleukin-6, and interleukin-3) that regulate megakaryocyte ploidy and platelet number and result in the production of larger platelets.
- Conditions
- Platelet Indices, White Blood Cell, Mean Platelet Volume, Myocardial Infarction, Obstructive Coronary Arteries, Short-Term Outcomes
- Being tested
- Coronary Angiography, SYNTAX Score
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary AngiographyOther
Coronary angiograms will be acquired digitally for quantification.
SYNTAX ScoreOther
Upon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Myocardial infarction with nonobstructive coronary arteries (MINOCA) patients Receives: Other: Coronary Angiography; Other: SYNTAX Score | |
| Control group | Healthy control individual. Receives: Other: Coronary Angiography; Other: SYNTAX Score |
What is being measured
The primary outcome is the main question the study is designed to answer.
White blood cell count to mean platelet volume ratio (WMR)
White blood cell count to mean platelet volume ratio (WMR) will be recorded.
Measured: Within 6 hours of symptom onset
Secondary outcomes (1)
Incidence of major adverse cardiovascular events
Incidence of major adverse cardiovascular events (MACE) will be recorded.
Measured: 1 month post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2025
- Study start1 Jan 2025
- Primary completion10 Jul 2025
- Study completion10 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Platelet IndicesStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Remon Saleh Adly, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07076732
- Sponsor's protocol ID
- Soh-Med-25-1-1PD
- Status last verified
- Mar 2026
- First submitted
- 12 Jul 2025
- Last updated
- 13 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Beyond Platelet Indices, WBC-to-MPV Ratio in Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA) Correlate With Short-Term Rather Than In-Hospital Outcomes
- ClinicalTrials.gov ID
- NCT07076732
- Acronym / sponsor ID
- Soh-Med-25-1-1PD
- Conditions
- Platelet Indices, White Blood Cell, Mean Platelet Volume, Myocardial Infarction, Obstructive Coronary Arteries, Short-Term Outcomes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 10 Jul 2025 (actual)
- Study completion
- 10 Jul 2025 (actual)
- First posted
- 22 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the role of platelet indices and the [White blood cell (WBC) /mean platelet volume (MPV)] ratio in correlation with angiographic profiles of patients diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA) to assess their predictive value for short-term clinical outcomes.
Detailed description
Globally, ischemic heart disease remains a significant cause of death, and its prevalence constantly increases. Around 5-15% of acute myocardial infarction (AMI) patients show nonobstructive (<50% stenosis) coronary arteries, named myocardial infarction with nonobstructive coronary arteries (MINOCA).
There are two main phases of inflammation during myocardial infarction: the inflammatory phase and the proliferative phase. The white blood cell (WBC) count and its subtypes have been investigated as potential predictors of cardiovascular outcomes in patients with coronary artery disease (CAD), serving as inflammatory markers.
The mean platelet volume (MPV) is determined in the progenitor cell, the bone marrow megakaryocyte. The platelet volume is found to be associated with cytokines (thrombopoietin, interleukin-6, and interleukin-3) that regulate megakaryocyte ploidy and platelet number and result in the production of larger platelets.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Study group | – | Other: Coronary Angiography, Other: SYNTAX ScoreMyocardial infarction with nonobstructive coronary arteries (MINOCA) patients |
| Control group | – | Other: Coronary Angiography, Other: SYNTAX ScoreHealthy control individual. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This case-control study will be performed at Sohag University Hospitals after approval from the institutional ethical committee.
Key inclusion criteria (3 listed)
- Age ≥18 years old.
- Both sexes.
- Patients with acute myocardial infarction (AMI). Myocardial infarction with nonobstructive coronary arteries (MINOCA) is diagnosed if a patient fulfilled the AMI criteria in the absence of obstructive coronary arteries (type I: <50% stenosis; or type II: no stenosis) as recommended by the recent American Heart Association statement that introduces an updated definition incorporating the 4th universal MI definition, which by agreement excludes Takotsubo syndrome and myocarditis from the eventual diagnosis of MINOCA.
Key exclusion criteria (9 listed)
- Previous history of MI or coronary revascularization (PCI or bypass surgery) with acute/chronic infection.
- Autoimmune diseases.
- Systemic inflammatory disease.
- Patients on treatment therapy which critically affects inflammatory cell count.
- Patients with malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary AngiographyCoronary angiograms will be acquired digitally for quantification. | Other | Control group, Study group |
| SYNTAX ScoreUpon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions. | Other | Control group, Study group |
Primary outcome
White blood cell count to mean platelet volume ratio (WMR)
Time frame: Within 6 hours of symptom onset
White blood cell count to mean platelet volume ratio (WMR) will be recorded.
1 secondary outcome
Incidence of major adverse cardiovascular events
Time frame: 1 month post-procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Platelet Indices
Not yet recruitingObservational study
Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications
Type 2 Diabetes Mellitus, Vascular Complications
Not yet recruitingObservational study
Serial Platelet Count and Indices for Predicting In-Hospital Mortality in Sepsis
Sepsis
Not yet recruitingObservational study
CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Not yet recruitingObservational study
CBC-Derived Inflammatory Indices in Acute Pancreatitis
Acute Pancreatitis, Pancreatitis
Active, not recruitingObservational study
Predictive Value of Nutritional and Inflammatory Indices for Postoperative Complications After Bariatric Surgery
Obesity (BMI > 35), Morbid Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Platelet Indices and White Blood Cell, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
White blood cell count to mean platelet volume ratio (WMR) (time frame: Within 6 hours of symptom onset). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.